Brain PET/MR Scans to Study Alzheimer, Parkinson, Epilepsy and Brain Tumors
Tests a combined brain PET/MR scan in adults with brain diseases, to aid diagnosis.
Plain-language title generated from the registry record
Registry title: Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT06092125, who can take part
Where in China
- Xuanwu HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xuanwu Hospital, Beijing
- Trial code
- NCT06092125
- Record updated
- 16 July 2025
- Original description
The goal of this clinical trial is to learn about the application of domestic PET/MR in major brain diseases. The main questions it aims to answer are:Read full original descriptionShow less
Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease
The goal of this clinical trial is to learn about the application of domestic PET/MR in major brain diseases. The main questions it aims to answer are:
* Overcome the bottleneck of early accurate diagnosis and treatment in major brain diseases clinical practice. * Promote the clinical application of domestic PET/MR, enhance international competitiveness. Participants will have a PET/MR scan of the brain.
Inclusion: Patients diagnosed with mild cognitive impairment (MCI) or Alzheimer's disease (AD), rapid eye movement sleep behavior disorder (RBD) or Parkinson's disease (PD), epilepsy, malignant brain tumors based on clinical guidelines; Patients admitted to our hospital for inpatient treatment.
Exclusion: patients with poorly controlled blood sugar and ineffective medication intervention; Patients who have undergone non-invasive/minimally invasive treatments such as radiotherapy or chemotherapy within the past three weeks. And Patients who have taken Alzheimer's disease-related and Parkinson's disease-related treatment drugs within the past month; Patients with persistent seizures or status epilepticus that cannot be controlled by medication, resulting in an inability to cooperate with the examination; Patients with absolute contraindications for PET/MR examination; Karnofsky Performance Score (KPS) <60.